Accelr8 Announces First European Presentation of Rapid Diagnostic Results for New Drug Resistance TestDENVER, Colo., March 1, 2011 – Accelr8 Technology Corporation (NYSE Alternext US: AXK) announced that one of its outside principal investigators received acceptance to present results of a new study in Europe. Researchers from the Washington University in St. Louis School of Medicine (the Barnes-Jewish Hospital) will present at the 21st annual ECCMID to be held May 7-10, 2011 in Milan, Italy. ECCMID is the European Congress of Clinical Microbiology and Infectious Disease, www.eccmid-icc2011.org. It is a major international meeting for professionals in clinical microbiology and Infectious Diseases Medicine. The study will describe alternative new tests, including Accelr8's BACcel&#8482 rapid diagnostic system, to identify an important new type of antibiotic resistance expressed by "Staph" bacteria. Standard culturing methods are unable to detect this new type of resistance, abbreviated as "hVISA." Staph often causes simple infections, but also causes life-threatening hospital-acquired infections. "MRSA" is the type of broadly drug resistant, dangerous Staph strain frequently cited in news stories as a "superbug." Physicians most often prescribe vancomycin if they suspect that a MRSA strain causes an infection. Staph variants have now emerged with declining vancomycin susceptibility. hVISA strains appear to be susceptible in standard culturing tests, but careful analysis in specialized research labs reveals important differences that indicate possible resistance. Since vancomycin is the cornerstone drug for suspected MRSA, hVISA may present a serious new threat. Unlike other methods, the BACcel&#8482 system eliminates the need for prior culturing, thereby reporting results on the same day rather than the 2-3 days required by culturing methods. The new BACcel&#8482 test for hVISA joins tests for other resistance types intended to be performed at the same time on the same patient specimen. According to David Howson, Accelr8's president, "the new presentation gives the large international community a close look at the BACcel&#8482 system concept and its performance. The new test may help investigators perform more definitive clinical studies to assess the spread of this emerging new threat," Howson concluded. About Accelr8 Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. Accelr8 is developing a rapid analytical platform for infectious pathogens, the BACcel&#8482 system, based on its innovative surface coatings, assay processing, and detection technologies. In addition, Accelr8 licenses certain of its proprietary technology for use in applications outside of Accelr8's own products. Certain statements in this news release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company's filings with the Securities and Exchange Commission. Accelr8 does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events. Contact OR John Metzger, of Metzger Associates Tom Geimer, of Accelr8 Technology Corp. +1.303.786.7000, ext. 2202 +1.303.863.8088 john@metzger.com tom.geimer@accelr8.com